top of page
Near-term Pipeline
IMMvention's mission is to create a globally accessible therapy, benefiting patients with limited or no access to gene therapies. Currently in preclinical stage, IMM-4800 has exceptional drug-like properties differentiating it from other BACH1 inhibitors and positioning it for success.
Anticipated milestones include IND enabling studies and Phase 1. Followed by Phase 2/3 trials and FDA approval submission leading to a transformative solution for Sickle Cell Disease worldwide.
IMM–004 Systemic
Clinical Candidate
IND
Phase 1a/b
Phase 2/3
Sickle Cell Disease (SCD)
Other Chronic Diseases
Indication Expansion
Partnered with Novo Nordisk
Pipeline Programs
IMM–002 Systemic
IMM–005 CNS
bottom of page